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December 2016 Innovation and Progress in Advanced sqCLC 2067ABSTRACT supportive care. Although the proportion of patients
14–16Squamous cell lung cancer (sqCLC) is an aggressive form of
cancer that poses many therapeutic challenges. Patients
tend to be older, present at a later stage, and have a high
incidence of comorbidities, which can compromise treat-
ment delivery and exacerbate toxicity. In addition, certain
agents routinely available for nonsquamous cell histologic
subtypes, such as bevacizumab and pemetrexed, are con-
traindicated or lack efficacy in sqCLC. Therapeutic progress
has been much slower for advanced sqCLC, with median
survival times of approximately 9 to 11 months in most
studies. Herein, we discuss the current therapeutic land-
scape for patients with sqCLC versus with nonsquamous
NSCLC. Current evidence indicates that new targeted
treatments, notably monoclonal antibodies such as ramu-
cirumab and necitumumab, and immunotherapies such as
nivolumab and pembrolizumab can provide survival pro-
longation, although the benefits are still relatively modest.
These incremental improvements, all realized since 2012, in
aggregate, will very likely have a clinically meaningful
impact for patients with sqCLC. We also discuss recent
genomic studies of sqCLC that have identified potentially
actionable molecular targets, as well as the relevant tar-
geted agents in clinical development. Finally, we discuss the
magnitude of survival benefit and the risk-to-benefit ratio
that would prove clinically meaningful in this underserved
patient population with unmet needs.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: NSCLC; Squamous cell lung cancer; Advanced;
Therapeutic landscape; Clinically meaningful outcomesIntroduction
NSCLC is a heterogeneous disease, with squamous
cell lung cancer (sqCLC) accounting for approximately
25% to 30% of cases.1,2 sqCLC is aggressive and often
challenging to treat, with treatment advances lagging
behind those of adenocarcinoma for several reasons: (1)
patients with sqCLC tend to be older3 and typically
present with advanced disease;4 (2) the central location
of most squamous tumors close to large blood vessels5
can present treatment challenges, including bleeding
and hemoptysis, that in turn can contraindicate certain
therapeutic agents; and (3) as the predominant risk
factor is smoking,1,6 patients have a higher incidence of
comorbidities than do their counterparts with non-
squamous NSCLC,7,8 and these in turn are associated
with poorer survival9–11 and a higher incidence of
adverse events after chemotherapy,12 which can
compromise treatment planning, delivery, and success.
As a result, active cancer interventions are often not
prescribed,9,13 with many patients receiving onlywith sqCLC has declined in developed countries,
sqCLC remains a major global concern,17–19 especially
in Eastern Europe, where smoking rates remain high.16
The U.S. Surveillance, Epidemiology and End Results
survey (1990–2005) revealed that between 1990 and
2005, significant improvements in survival were
observed for patients with metastatic NSCLC, irre-
spective of histologic subtype; however, between 2002
and 2005, survival significantly increased for patients
with metastatic adenocarcinoma versus for patients with
sqCLC.20 This observation coincided with the approval
and increased use of EGFR tyrosine kinase inhibitors
(TKIs) such as gefitinib and erlotinib during the latter
time period. The benefits of EGFR TKIs and other agents
targeting oncogenic drivers, such as anaplastic lym-
phoma kinase (ALK) inhibitors, have largely been
confined to advanced adenocarcinoma, in which these
molecular abnormalities are almost exclusively
observed.21–25 Until late 2015, no targeted therapies
were approved for first-line treatment of sqCLC,26–33 and
median survival in advanced sqCLC remained static at
approximately 9 to 11 months34,35 versus approximately
12 to 14 months for nonsquamous NSCLC.34–38 New
treatment strategies that would provide clinically
meaningful outcomes without adversely affecting quality
of life (QoL) are therefore needed for sqCLC. Fortunately,
intense research into the molecular pathogenesis of
sqCLC is ongoing and novel targeted agents and immu-
notherapies have recently been approved.
This review describes the importance of incremental
innovation and progress in achieving clinically mean-
ingful improvements in survival for patients with sqCLC.
Current treatment options, the recent impact of immu-
notherapy approaches, and the potential impact of
emerging biomarkers and targeted therapies on survival
for sqCLC are discussed.Incremental Progress in the Treatment
of NSCLC
The improvement in survival for patients with
advanced NSCLC, including sqCLC, has been the result
of relatively small incremental gains rather than sub-
stantial increases due to individual treatment
developments.20 Over the past three decades, stepwise
increases in survival for advanced NSCLC have paralleled
the change from first-line single-drug platinum treat-
ment to platinum-doublet chemotherapy to platinum-
doublet chemotherapy with or without targeted
therapies (for nonsquamous NSCLC only) (Fig. 1 and
Table 1)34,35,37–49 as well as the advent of second-line
and third-line regimens, with a positive impact on
survival.50–54
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Figure 1. Examples of incremental advances in survival for first-line advanced/metastatic NSCLC.34,35,37–48
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1980s), median survival for advanced NSCLC was 3 to 5
months.55 The advent of cytotoxic platinum doublets in
the 1990s increased median overall survival (OS)
compared with that provided by single agents, with the
increase being similar for adenocarcinoma and sqCLC
and reaching approximately 8 to 11 months after the
introduction of platinum doublets containing paclitaxel,
vinorelbine, or gemcitabine.40–48 Triplet therapy yielded
greater toxicity but no additional survival benefit versus
that from two-drug combinations.56,57 Subsequent
studies showed discordance between safety or efficacy
outcomes for bevacizumab and pemetrexed by histologic
subtype, with benefits confined to patients with non-
squamous NSCLC versus sqCLC.27,34
First-Line Therapy for Nonsquamous NSCLC
In the mid-2000s, the vascular endothelial growth
factor inhibitor bevacizumab in combination with
platinum-based chemotherapy demonstrated a survival
benefit compared with chemotherapy alone in patients
with a nonsquamous histologic subtype and no ante-
cedent history of hemoptysis (see Table 1).37,38 More
recently, in patients with adenocarcinoma, pemetrexed-
cisplatin significantly improved median OS versus with
gemcitabine-cisplatin (see Table 1).34 The survival ben-
efits of pemetrexed extended into the first-line mainte-
nance setting irrespective of whether patients received
pemetrexed as a component of their initial platinum-
based chemotherapy combination.36,58
In patients with activating EGFR mutations and ALK
rearrangements, EGFR TKIs and crizotinib, respectively,
have significantly improved objective response rates and
progression-free survival (PFS), with major reductions in
toxicity compared with standard platinum-doublet
chemotherapy.59–65 For these reasons, current guide-
lines indicate the need for molecular testing and treat-
ment with EGFR TKIs or ALK inhibitors for patients with
positive test results.66–69 In the case of afatinib, asecond-generation EGFR TKI and ErbB family blocker, a
major survival advantage has been observed compared
with that provided by chemotherapy in patients with
exon 19 deletion.70
Demonstrating OS benefits for EGFR TKIs and crizo-
tinib has proved challenging in randomized studies on
account of crossover treatments after first-line therapy.
However, evidence of improved OS is available from
historical comparisons, retrospective analyses, and
comparisons between patients who did and did not
receive targeted treatments.22,71,72
First-Line Therapy for sqCLC
More modest improvements in survival have been
observed for sqCLC. Activating EGFR mutations or
anaplastic lymphoma receptor tyrosine kinase gene
(ALK) rearrangements are exceedingly rare in
sqCLC,21,23–25 and most patients with sqCLC do not un-
dergo molecular testing for these alterations unless they
have minimal or no prior tobacco exposure. Conse-
quently, few treatment-naive patients with sqCLC are
candidates to receive EGFR TKIs or ALK inhibitors.
Additionally, bevacizumab is contraindicated in
sqCLC73,74 because of pulmonary hemorrhage, which
was first observed in a randomized phase II trial,27
prompting the exclusion of patients with sqCLC from
subsequent phase III trials.37
Retrospective analyses of earlier studies in NSCLC
with platinum-doublet chemotherapy did not show a
significant difference in survival outcomes between pa-
tients with nonsquamous and squamous histologic sub-
types (see Table 1).45,46 In a later large randomized trial, a
survival benefit was observed in sqCLC for gemcitabine-
cisplatin versus for pemetrexed-cisplatin (see
Table 1).34 For sqCLC, a platinum agent plus either gem-
citabine or a taxane remains the most frequently used
first-line combination,75–77 with the selection of agents
generally based on toxicity and preexisting medical is-
sues. Yet, over the past decade, modest progress has been
December 2016 Innovation and Progress in Advanced sqCLC 2069observed with the introduction of nab-paclitaxel. In a
phase III study (N ¼ 1052), first-line nab-paclitaxel–
carboplatin demonstrated a significant improvement in
response rate versus that provided by paclitaxel-
carboplatin for patients with sqCLC (41% versus 24%,
response rate ratio ¼ 1.68; 95% confidence interval (CI):
1.27–2.22, p < 0.001).35 Although the improvement in
response rate did not translate into a significant OS
benefit in either sqCLC (10.7 versus 9.5 months, hazard
ratio [HR] ¼ 0.89) or nonsquamous NSCLC (13.1 versus
13.0 months, HR ¼ 0.95 [see Table 1]),35 nab-paclitaxel
plus a platinum agent is a first-line treatment option for
patients with sqCLC. Recently, the cisplatin derivative
nedaplatin plus docetaxel showed a survival benefit
versus with cisplatin-docetaxel in Japanese patients with
sqCLC (see Table 1).49
When the improvements in OS afforded by individual
first-line therapies in advanced NSCLC are viewed criti-
cally, it is evident that they have generally been modest
irrespective of histologic subtype. In aggregate, however,
these incremental improvements have yielded much
larger clinically important benefits.
Second- and Subsequent-Line Therapy for
Nonsquamous NSCLC and sqCLC
Single-agent second- or subsequent-line therapy has
also provided a modest survival benefit in advanced
NSCLC.53,54,78,79 Docetaxel was the first agent approved
in the United States for second-line NSCLC therapy.
Although the efficacy and safety of docetaxel in combi-
nation with other agents (e.g., erlotinib, vinorelbine, or
gemcitabine) has been investigated in the second-line
setting, several studies showed no improvement in effi-
cacy and/or increased toxicity with combination therapy
over docetaxel alone.80–84 Furthermore, phase III trials
seeking to improve survival by adding targeted agents
such as cetuximab85 or ziv-aflibercept86 were negative.
The differential effects of pemetrexed by histologic
subtype have also been demonstrated in the second-line
setting. Although similar survival outcomes were
observed overall in a phase III trial comparing peme-
trexed with docetaxel,79 a secondary analysis showed a
survival benefit for pemetrexed for nonsquamous
NSCLC, whereas patients with sqCLC fared better with
docetaxel.50 This observation contributed to a change in
indication of pemetrexed to exclude sqCLC in the
second-line setting.87
For targeted agents such as erlotinib in unselected
patients, including those with sqCLC, survival benefits
have been observed only in comparison with placebo
controls or best supportive care.54,78 Comparisons of
erlotinib or gefitinib with docetaxel have generally
shown similar survival outcomes in unselected patients
or patients with EGFR wild-type tumors,51,88,89 althoughOS was significantly longer with docetaxel than with
erlotinib (8.2 versus 5.4 months, HR ¼ 0.73, 95% CI:
0.53–1.00, p ¼ 0.05) in the TAILOR study.51
Targeted Agents and Immunotherapy
Approaches in sqCLC
Considerable research is being focused on novel tar-
geted agents and immunotherapy approaches for
advanced sqCLC. Necitumumab is the first targeted agent
to be approved in the first-line setting, and three agents
have been approved in the second-line setting.
Antiangiogenesis
Although targeting angiogenesis has proven chal-
lenging in sqCLC owing to the increased risk for pul-
monary hemorrhage with agents such as
bevacizumab,27,29 the antiangiogenic vascular endothe-
lial growth factor receptor 2 inhibitor ramucirumab plus
docetaxel has been approved in the United States and
Europe for the second-line treatment of metastatic or
advanced NSCLC, respectively, in all histologic sub-
types,90,91 thereby expanding the limited therapeutic
armamentarium for sqCLC. In the second-line phase III
REVEL study (N ¼ 1253), ramucirumab plus docetaxel
demonstrated improved median OS versus with doce-
taxel alone in the overall population (10.5 versus 9.1
months, HR ¼ 0.86, 95% CI: 0.75–0.98, p ¼ 0.023).92
Comparable, but nonsignificant, OS benefits were
observed in the sqCLC subgroup (n ¼ 328 [26%], 9.5
versus 8.2 months, HR ¼ 0.88, 95% CI: 0.69–1.13)
(Fig. 2). Similar benefits were observed in response rate
and PFS. Of note, ramucirumab did not increase toxicity
(in particular, the rates of hemoptysis or pulmonary
hemorrhage) in the sqCLC subgroup versus in the non-
squamous subgroup.
Anti-EGFR
EGFR amplification occurs in 7% to 10% of sqCLC
tumors,21 and overexpression of the EGFR protein is
more common in sqCLC than in nonsquamous NSCLC.93
EGFR overexpression correlates with increased gene
copy number, and an association between increased
gene copy number and poor prognosis has been
observed.93 The phase III FLEX trial of first-line therapy
(N ¼ 1125) investigated the addition of the EGFR in-
hibitor cetuximab to chemotherapy.94 A statistically
significant but clinically modest improvement in OS was
observed with cetuximab plus chemotherapy versus
with chemotherapy alone in patients with sqCLC (10.2
versus 8.9 months, HR ¼ 0.80, 95% CI: 0.64–1.00)
compared with in those with adenocarcinoma (12.0
versus 10.3 months, HR ¼ 0.94, 95% CI: 0.77–1.15). A
meta-analysis of four randomized trials examining the
Table 1. Incremental Improvements in Survival with First-Line Treatment of Advanced/Metastatic NSCLC
Study Population Regimen
Median OS, mo
All Histologic
Subtypes Nons amous Squamous
Single-agent platinum chemotherapy
EST 1583 (n ¼ 699)a,39 Carboplatin 7.3
Platinum-doublet chemotherapy
Wozniak et al. (n ¼ 432)44 Advanced NSCLC Cisplatin 6
PS 0–1 Vinorelbine-cisplatin 8
(p ¼ 0.018)
Sandler et al. (n ¼ 522)43 Advanced NSCLC Cisplatin 7.6
Gemcitabine-cisplatin 9.1
(p ¼ 0.004)
ECOG 1594 (n ¼ 1207)42,45 Stage IIIb/IV Platinum doublet 7.9 Aden arcinoma:
PS 0–2 Paclitaxel-cisplatin 7.8 9.1 6.9
Gemcitabine-cisplatin 8.1 8.1 9.4
Docetaxel-cisplatin 7.4 7.7 8.1
Paclitaxel-carboplatin 8.1 7.6 9.3
Rosell et al. (n ¼ 618)41 Stage IIIb/IV Paclitaxel-carboplatin 8.2
PS 0–2 Paclitaxel-cisplatin 9.8
(HR ¼ 1.22, 95% CI:
1.06–1.40, p ¼ 0.019)
TAX 326 (n ¼ 1218)40 Stage IIIb/IV Vinorelbine-cisplatin 10.1
Docetaxel-cisplatin 11.3
(p ¼ 0.044)
Lilenbaum et al. (n ¼ 561)47 Stage IIIb/IV Paclitaxel 6.7
PS 0–2 Paclitaxel-carboplatin 8.8
(HR ¼ 0.91, 95% CI:
0.77–1.17, p ¼ 0.25)
GLOB3 (n ¼ 381)48 Stage IIIb/IV Aden arcinoma:
KPS 80% Vinorelbine-cisplatin 9.9 11.7 8.9
Docetaxel-cisplatin 9.8 11.6 9.8
(p ¼ 0.58)
SWOG (S9308, S9509,
and S0003; n ¼ 792)46
Stage IIIb (pleural effusion
only)/IV
Aden arcinoma:
PS 0–1 Paclitaxel-carboplatin 9.1 8.8
Vinorelbine-cisplatin 8.1 6.9
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Table 1. Continued
Study Population Regimen
Median OS, mo
All Histologic
Subtypes Nons uamous Squamous
Newer cytotoxics
Scagliotti et al. (n ¼ 1725)34 Stage IIIb/IV Pemetrexed-cisplatin 10.3 11.8 9.4
PS 0–1 Gemcitabine-cisplatin 10.3 10.4 10.8
(HR ¼ 0.94, 95% CI:
0.84–1.05)
(HR ¼ 0.81, 95% CI:
0.7 –0.94, p ¼ 0.005)
(HR ¼ 1.23, 95% CI:
1.00–1.51, p ¼ 0.05)
Socinski et al. (n ¼ 1052)35 Stage IIIb/IV Nab-paclitaxel-carboplatin 12.1 13.1 10.7
PS 0–1 Paclitaxel-carboplatin 11.2 13.0 9.5
(HR ¼ 0.92, 95% CI:
0.80–1.07, p ¼ 0.27)
(HR ¼ 0.95) (HR ¼ 0.89)
WJOG5208L (n ¼ 355)49 Stage IIIb/IV or recurrent Nedaplatin-docetaxel 13.6
PS 0–1 Cisplatin-docetaxel 11.4
(HR ¼ 0.81, 95% CI:
0.65–1.02, p ¼ 0.037)
Targeted therapies
Sandler et al. (n ¼ 878)37,38 Stage IIIb/IV Aden arcinomab:
PS 0–1 Paclitaxel-carboplatin 10.3
Bevacizumab + paclitaxel-
carboplatin
14.2
(HR ¼ 0.69, 95% CI:
0.5 –0.83)
aOnly data for carboplatin arm are shown.
bOS for nonsquamous NSCLC: 10.3 months with paclitaxel-carboplatin versus 12.3 months with bevacizumab + paclitaxel-carboplatin (HR ¼ 0.80, 95% C .69–0.93).
OS, overall survival; PS, performance status; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky perf mance status.
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Figure 2. Overall survival in the phase III REVEL study. (A) Patients with nonsquamous NSCLC; (B) Patients with squamous cell
lung cancer. CI, confidence interval; HR, hazard ratio; sqCLC, squamous cell lung cancer. Reprinted with permission from
Garon et al.92
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Figure 3. Overall survival in patients with squamous cell lung
cancer (sqCLC) with high EGFR expression in the phase III
FLEX99 and SQUIRE100 studies. CI, confidence interval; HR,
hazard ratio.
December 2016 Innovation and Progress in Advanced sqCLC 2073risk-to-benefit profile of cetuximab as first-line therapy
for advanced NSCLC demonstrated that the addition of
cetuximab to platinum-based chemotherapy significantly
improved OS, PFS, and response rate, with a manageable
safety profile versus with chemotherapy alone.95
It was hoped that identification of predictive bio-
markers such as EGFR protein expression or gene copy
number would allow an informed selection of patients
most likely to benefit from therapies targeting EGFR.
Increased EGFR gene copy number by fluorescent in situ
hybridization (FISH) was first shown to be predictive for
cetuximab efficacy in a phase II study with 229
chemotherapy-naive patients with advanced NSCLC.96
However, in a retrospective analysis of the first-line
BMS099 study of cetuximab plus carboplatin-taxane
versus carboplatin-taxane (which did not show a sig-
nificant OS benefit with cetuximab), no significant as-
sociations were observed for EGFR protein expression
by immunohistochemistry or EGFR FISH positivity.97,98
In an analysis of patients from the phase III FLEX
study with available tumor EGFR immunohistochemistry
data (1121 of 1125 patients), the median OS of patients
in the high–EGFR expression group (H-score 200) was
longer for cetuximab plus chemotherapy than for
chemotherapy alone (12.0 versus 9.6 months,
HR ¼ 0.73, 95% CI: 0.58–0.93, p ¼ 0.011), with no
meaningful increase in side effects.99 No corresponding
survival benefit was observed in the low–EGFR expres-
sion group (H-score <200). Similarly, prolonged OS was
observed in the sqCLC subgroup with high EGFR
expression with the cetuximab combination versus with
chemotherapy alone (HR ¼ 0.62, 95% CI: 0.43–0.88)
(Fig. 3).99 Of note, determination of the H-score cutoff of
200 or higher was based on association with response
rate, and the effect on OS was assessed on the same
patient population. A formal randomized, phase III study(SWOG 0819; NCT00946712) examined cetuximab effi-
cacy (with variable inclusion of bevacizumab) in the
first-line advanced NSCLC (including sqCLC) setting,
with a subgroup analysis investigating the predictive
role of increased EGFR gene copy number measured by
FISH.101,102 Although cetuximab in combination with
chemotherapy did not significantly increase OS versus
chemotherapy alone in the overall population, OS was
significantly improved in the sqCLC FISH–positive sub-
group (11.8 versus 6.4 months, HR ¼ 0.56, 95% CI:
0.37–0.84, p ¼ 0.006).103
The phase III SQUIRE trial of first-line necitumumab,
a second-generation EGFR inhibitor, combined with
gemcitabine-cisplatin in patients with metastatic sqCLC
(N ¼ 1093) demonstrated significant improvements in
OS versus with gemcitabine-cisplatin alone (11.5 versus
9.9 months, HR ¼ 0.84, 95% CI: 0.74–0.96, p ¼ 0.01), in
PFS (5.7 versus 5.5 months, HR ¼ 0.85, 95% CI: 0.74–
0.98, p ¼ 0.02), and in disease control rate (82% versus
77%, p ¼ 0.043).100 An exploratory analysis demon-
strated that patients with sqCLC with high EGFR
expression (H-score 200), but not low EGFR expres-
sion (H-score <200), had significantly improved OS with
the addition of necitumumab versus with gemcitabine-
cisplatin alone (see Fig. 3). However, the difference in
HR between the two EGFR expression groups was not
significant (interaction p value ¼ 0.24). Further analysis
showed a trend toward greater OS benefit with necitu-
mumab versus with chemotherapy alone in patients with
EGFR FISH–positive tumors (12.6 versus 9.2 months, HR
¼ 0.70, 95% CI: 0.52–0.96).104 Although the same posi-
tive predictive trend for EGFR gene copy number
assessed by FISH was seen in both the SQUIRE and
SWOG 0819 studies (see earlier),102,104 further valida-
tion of FISH as a predictive assay for anti-EGFR anti-
bodies must be performed before valid clinical
conclusions can be drawn. The safety profile of necitu-
mumab was consistent with that expected for an EGFR
antibody in combination with chemotherapy, with
venous thromboembolic events more common and
increased incidence of skin reactions with a grade of 3 or
higher and hypomagnesemia.100 Necitumumab plus
gemcitabine-cisplatin is approved in the United States
for the treatment of metastatic sqCLC33 and in Europe
for the treatment of advanced EGFR-expressing
sqCLC,105 and it constitutes a true incremental advance
for patients with sqCLC in the first-line setting. However,
the lack of a validated predictive biomarker for anti-
EGFR monoclonal antibodies remains an issue.
Finally, afatinib recently demonstrated superiority
over erlotinib for disease control rate (51% versus 40%,
p¼0.002), PFS (2.6 versus 1.9months, HR¼0.81, 95%CI:
0.69–0.96, p ¼ 0.010), and OS (7.9 versus 6.8 months,
HR ¼ 0.81, 95% CI: 0.69–0.95, p ¼ 0.008) in second-line
2074 Langer et al Journal of Thoracic Oncology Vol. 11 No. 12advanced sqCLC.106 In early 2016, it was approved in both
the United States and Europe for use in this setting.107,108
Immunotherapy Approaches in sqCLC
Multiple agents targeting immunologic pathways are
in clinical development for NSCLC, including sqCLC. The
cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4)
and anti–programmed cell death protein 1 (anti–PD-1)
pathways are two checkpoint pathways critical for con-
trolling T-cell immune responses, which coordinate the
immune response to tumors.109 By targeting these
pathways, immunotherapies aim to restore the immune
system and allow T cells to function appropriately
against tumors.
Ipilimumab, an anti–CTLA-4 monoclonal antibody,
prevents T-cell downregulation.110 In subset analyses of a
phase II study in all NSCLC histologic subtypes, a phased
regimen of ipilimumab plus carboplatin-paclitaxel, in
which ipilimumab was grafted onto the third cycle of
carboplatin-paclitaxel, exhibited a trend toward greater
PFS benefits versus with carboplatin-paclitaxel alone for
patients with sqCLC (HR ¼ 0.55, 95% CI: 0.27–1.12) than
for patients with nonsquamous NSCLC (HR ¼ 0.82, 95%
CI: 0.52–1.28) without overtly exacerbating the toxicities
associated with carboplatin-paclitaxel.110 Similar results
were observed for OS, with a nonsignificant improvement
in 3-month survival for phased ipilimumab plus
carboplatin-paclitaxel compared with for carboplatin-
paclitaxel alone in patients with sqCLC (10.9 versus 7.9
months, HR¼ 0.48, 95% CI: 0.22–1.03), but no benefit for
nonsquamous NSCLC (HR ¼ 1.17, 95% CI: 0.74–
1.86).110,111 This observation laid the foundation for
ongoing phase III trials investigating ipilimumab in com-
bination with carboplatin-paclitaxel for first-line treat-
ment of metastatic/recurrent sqCLC (NCT01285609 and
NCT02279732 [enrollment complete]), which started in
2011 and 2014, respectively.
The U.S. and European approvals of the anti–PD-1
agent nivolumab for second-line treatment of advanced
sqCLC were based on the results of the phase III Check-
mate 017 study of nivolumab versus docetaxel
(N ¼ 272).112 Patients who received nivolumab had
significantly longermedian OS than patientswho received
docetaxel (9.2 versus 6.0 months, HR ¼ 0.59, 95% CI:
0.44–0.79, p < 0.001), increased median PFS (3.5 versus
2.8 months, HR for death or disease progression ¼ 0.62,
95% CI: 0.47–0.81, p < 0.001), and increased response
rate (20% versus 9%, p ¼ 0.008). The 1-year survival
rates were 42% and 24%, respectively. Median duration
of response was not reached in the nivolumab group,
whereas it was 8.4months in the docetaxel group. Grade 3
or 4 treatment-related adverse events were reported less
frequently with nivolumab than with docetaxel (7%
versus 55%). In an exploratory analysis in a limitednumber of patients that used low cutoffs for programmed
death ligand 1 (PD-L1) expression, the OS and PFS bene-
fits with nivolumab were observed regardless of levels of
tumor expression of PD-L1.
Another anti–PD-1 agent, pembrolizumab, received
accelerated approval in the United States for second-line
treatment of patients with advanced NSCLC, including
sqCLC, whose tumors express PD-L1. Approval was
based on the results of a subgroup analysis of patients in
the KEYNOTE-001 study113 with a PD-L1 expression
tumor proportion score (TPS) of 50% or higher (n ¼ 61)
for whom a response rate of 41%114 and long duration
of response was observed.115Additionally, in the second-
line phase II/III KEYNOTE-010 study (N ¼ 1034),
pembrolizumab demonstrated longer OS versus with
docetaxel in patients with both a PD-L1 TPS of at least
50% and a TPS of at least 1%.116 Other anti–PD-1 and
anti–PD-L1 agents, such as atezolizumab and durvalu-
mab, are in phase III development for advanced NSCLC,
including sqCLC.
PD-L1 expression as a predictive biomarker for
treatments targeting the PD-1 pathway is still being
investigated.117,118 The preliminary evidence suggests
that smoking may correlate with heightened response to
anti–PD-L1 agents119 and that the benefits of these
agents may be more pronounced in those with greater
mutation burden,120 as is typical in advanced sqCLC.21
Immunotherapy approaches for sqCLC are highly
promising, but additional data from large randomized
clinical trials are needed to fully evaluate their efficacy
and safety profiles. However, the approval of nivolumab
in sqCLC has proved transformative already, with doce-
taxel relegated to the third-line setting.
Potential Biomarkers and Targeted Therapies
The genome of lung adenocarcinoma has been
increasingly classified since the early 2000s; as of 2015,
multiple actionable molecular targets have been identi-
fied.22 Until recently, however, little was known of po-
tential oncogenes in sqCLC.21,23,25,121,122 It is apparent
that the oncogenic profiles of adenocarcinoma and
sqCLC are different. SqCLC tumors are genetically com-
plex and have a high frequency of mutations in proteins,
many of which are not mutually exclusive.21,25 Rather
than single oncogenic driver mutations that may be
targeted in adenocarcinoma, the molecular targets for
therapy in sqCLC involve overexpression or amplifica-
tion of multiple receptors.
Targets include EGFR expression (as already
described), ErbB family inhibition, fibroblast growth
factor receptor-1 (FGFR1) amplification, discoidin
domain receptor tyrosine kinase 2 (DDR2) muta-
tions, and phosphoinositide-3-kinase pathway changes
(phosphatidylinositol 3-kinase catalytic subunit alpha
Table 2. Targeted Agents Directed against FGFR1 Amplification in sqCLC in Phase II/III Clinical Development for Advanced/
Metastatic sqCLC
Targeted
Agent
Development
Phase
Treatment
Setting
Treatment
Regimen Study No.
AZD4547 II
II/III
Maintenance
Second-line
Single agent
Single agent
NCT02117167
NCT02154490
Ponatinib II All lines Single agent NCT01935336
Lucitanib II Second-line Single agent NCT02109016
Nintedanib II First-line
Second- / third-line
Combination with gemcitabine-cisplatin
Single agent
NCT01346540
NCT01948141
Dovitinib II Second- / third-line Single agent NCT01861197
sqCLC, squamous cell lung cancer; FGFR1, fibroblast growth factor receptor-1.
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or deletion) (Table 2 and Fig. 4).21,23,25,93,123–125
FGFR1 amplification has been identified in up to 25%
of sqCLC tumor specimens21,23,123,126 and has been
associated with tumor growth and survival.123 When a
3.5-fold amplification cutoff is used, the FGFR1 amplifi-
cation rate is approximately 5% in sqCLC.127 Alterations
in the phosphoinositide-3-kinase pathway affect cell
survival and proliferation128 and are common in sqCLC,
with phosphatidylinositol 3-kinase catalytic subunit
alpha mutations and phosphatase and tensin homolog
mutations or deletion occurring in approximately 30%
to 50% of tumors.21,23 Actionable targets that occur with
low frequency include mutations in the discoidin domain
receptor tyrosine kinase 2 gene (DDR2) (w3%–
4%)25,124,129 and ErbB2 amplification (4%).130 Preclini-
cal studies suggest that DDR2 mutations may promote
squamous cell proliferation, migration, and invasion129Pathway
Actionable targets 
(frequency) and 
targeted agents
RTK PI3K(30-50%
EGFR 
(amplification 
~7–10%)
ErbB2/ErbB3 
alteration 
(2–4%)
FGFR1 
amplification
(up to 25%)
DDR2 
mutation
(~3–4%)
Anti-EGFR mAbs
(necitumumab, 
cetuximab)
ErbB family inhibitors
(afatinib)
FGFR inhibitors
(AZD4547, ponatinib, 
lucitanib, nintedanib, 
dovitinib)
Dasatinib
PIK3CA m
(16%
PTE
deletion/m
(15%
AKT1
overact
(~20
Figure 4. Selected signaling pathwayswith actionablemolecular t
targeted agents approved or in development.21,25,125 RTK, recep
noblastoma; ErbB2/3, erb-b2 receptor tyrosine kinase 2/3; FGFR
ceptor tyrosine kinase 2; PIK3CA, phosphatidylinositol 3-kinase ca
AKT, alpha serine/threonine-protein kinase; CDKN2A, cyclin-depenand may be successfully targeted by dasatinib124; how-
ever, a phase II study of dasatinib in advanced sqCLC in
unselected patients was terminated on account of excess
dasatinib toxicity.131
The deployment of targeted therapies is challenging
in sqCLC because of the genetic diversity, mutation
burden, and lack of clear oncogenic drivers in this dis-
ease. Thus far, novel targeted therapies for sqCLC have
demonstrated only marginal to modest clinical benefits
as monotherapies.132–134 Ultimately, we may need to
wait until novel combinations of targeted agents or
targeted agents with conventional chemotherapy are
identified before substantial improvements in survival
are observed.
New Clinical Trial Designs in sqCLC
The diverse genetic characteristics of sqCLC also
make it challenging to recruit enough patients from an) RB
PI3K inhibitors
(taselisib, buparlisib)
CDK4/6 inhibitors
(palbociclib, 
abemaciclib)
utation 
)
N 
utation
)
/2/3
ivation
%)
CDKN2A inactivation
(silencing/mutation/deletion)
(72%)
p16INK4
downregulation
argets (and their frequencies) in squamous cell lung cancerwith
tor tyrosine kinase; PI3K, phosphoinositide-3-kinase; RB, reti-
, fibroblast growth factor receptor; DDR2, discoidin domain re-
talytic subunit alpha; PTEN, phosphatase and tensin homolog;
dent kinase inhibitor 2A;CDK4/6, cyclin-dependent kinase4/6.
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pies. The biomarker-driven Lung Cancer Master Protocol
(Lung-MAP; S1400) study of second or greater lines of
treatment of recurrent advanced/metastatic sqCLC
(NCT02154490) aims to address this issue.135 Lung-MAP
uses a targeted screening approach; patients are tested
only once according to a “master protocol” and assigned
to different substudies on the basis of biomarker iden-
tification, with each evaluating a different targeted drug.
Patients who are ineligible for the biomarker-driven
substudies receive nivolumab or nivolumab plus ipili-
mumab. The Lung-MAP study design has already
changed to accommodate the approvals of nivolumab
and pembrolizumab by moving to second line and
beyond, and it will continue to evolve as more
biomarkers with targeted therapies are identified.
Defining Clinically Meaningful
Improvements in Survival in sqCLC
Given the modest clinical benefits observed with new
targeted agents and the additional survival gains with
immunotherapies, the question arises as to what will
constitute a clinically meaningful advance for patients
with sqCLC in ongoing and future clinical trials. In 2012,
in the context of future clinical trial design, the American
Society of Clinical Oncology (ASCO) Cancer Research
Committee convened four disease-specific working
groups composed of experts in pancreatic, breast, colon,
and lung cancers.136 The aim was to help guide
the development of randomized phase III trials that
would produce clinically meaningful benefits for
patients—either significantly improved survival, QoL, or
both. All four working groups chose OS as the primary
measure of clinically meaningful outcome, although it
was noted that PFS and other surrogate end points in
clinical trials remain of value, as prolongation of PFS
would potentially provide longer palliation of symptoms
and better QoL. Additionally, it was recommended that
incremental gains in survival should not be accompanied
by unacceptable increases in toxicity compared with
that of current treatments, and new treatments that
exhibited increased toxicity would also need to yield
relatively greater increases in survival.
The working group recommendation for sqCLC
stipulated a minimum improvement in median OS of 2.5
to 3 months, with a target HR of 0.77 to 0.80 as a
clinically meaningful outcome for trials of first-line
therapy, but these recommendations were not made
for second- or third-line therapy.136 It is apparent from
the small incremental improvements in survival that are
evident from the clinical trial data for NSCLC in recent
decades that many agents in the current therapeutic
armamentarium would not have been approved ifregulatory authorities had based their decisions strictly
on the ASCO working group criteria.136 Therefore, when
a clinically meaningful outcome is being determined,
new treatments should be compared with the current
standard of care in the context of the balance between
efficacy (response, PFS, OS, and patient-reported out-
comes) and toxicity. This is particularly important in
advanced sqCLC, in which many patients are elderly,
have challenging comorbidities, or have poor perfor-
mance status, each of which already affects whether
they can receive chemotherapy.9,13,137,138
Conclusions
The characteristics of patients with sqCLC make it
challenging to develop new treatment options, leading to
a lack of targeted first-line treatments for this disease.
Therefore, every incremental innovation and improve-
ment in survival, QoL, and risk-to-benefit profile may
yield a clinically meaningful impact for patients, even if
it does not necessarily measure up to the new ASCO
standards. The benefits provided by anti–PD-1 agents
(nivolumab and pembrolizumab) constitute an impor-
tant exception. Importantly, given the genetic complexity
of sqCLC tumors, the potential clinical impact of
targeting individual molecular drivers should not
be overestimated. Current evidence suggests that treat-
ment advances for sqCLC will continue to be incre-
mental over the next 5 years. Although new targeted
therapies may individually result in small therapeutic
gains for sqCLC, when considered in aggregate, these
effects may provide important, clinically meaningful
benefits for patients. Indeed, only when we examine the
complete set of data, often accumulated over a long
period of time, can we appreciate the full clinical value
that incremental innovations in cancer treatments bring
to patients.
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